XENCO INC Action · US98401F1057 · XNCR · A1W96L (XNMS) États-Unis · Healthcare — cotations et cours en temps réel, données d'entreprise, dividendes, fondamentaux et analyse de portefeuille IA sur MoneyPeak

Aperçu

Analyse alimentée par l’IA

Analyse fondamentale

Découvrez ce que disent vraiment les chiffres — avant le marché

Analyser maintenant

Sentiment des actualités

Les actualités d’aujourd’hui sont-elles un signal d’achat ou un avertissement ?

Analyser maintenant

Acheter / Conserver / Vendre

Faut-il acheter, conserver ou vendre ? Obtenez l’avis de l’IA dès maintenant.

Analyser maintenant

Évaluation des risques

Détectez les risques cachés avant qu’ils n’impactent votre portefeuille.

Analyser maintenant

Juste valeur

Cette action est-elle bon marché, correctement valorisée ou surévaluée ?

Analyser maintenant

Dernières analyses d’IA sur XENCO INC

Résumé de la Note des Analystes

Achat

Achat fort

Achat

Conserver

Vente

Vente forte

Pas de cours

05.06.2026 20:40

Cours actuels de XENCO INC

Bourse	Ticker	Devise	Dernier échange	Cours	Variation journalière
NASDAQ	XNCR	USD	05.06.2026 20:40	11,60 USD	-0,41 USD -3,41 %
IEX	XNCR	USD	05.06.2026 19:59	11,78 USD	-0,23 USD -1,96 %
Quotrix	XIRSDL57.DUSD	EUR	05.06.2026 05:27	10,30 EUR	-
Düsseldorf	XIRSDL57.DUSB	EUR	04.06.2026 17:30	10,10 EUR	-

Flottant et Liquidité des Actions

Flottant Libre 73,49 %

Actions en Flottant 54,48 M

Actions en Circulation 74,14 M

Fonds investis

Les fonds suivants ont investi dans XENCO INC :

Fonds Loncar Cancer Immunotherapy ETF	Vol. en millions 1.611,04	Part (%) 3,37 %
Fonds Virtus Biotech Clinical Trials ETF	Vol. en millions 229,67	Part (%) 0,54 %
Fonds ALPS Medical Breakthroughs ETF	Vol. en millions 1.233,16	Part (%) 0,53 %
Fonds Invesco S&P SmallCap Health Care ETF	Vol. en millions 2.328,66	Part (%) 0,44 %
Fonds iShares Genomics Immunology and Healthcare ETF	Vol. en millions 982,88	Part (%) 0,30 %

Profil de l'entreprise pour XENCO INC Action

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.